All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Why is the German experience with commercial CAR T inferior to published study data?
Bookmark this article
During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Lymphoma Hub spoke to Wolfgang Bethge, University Hospital Tübingen, Tübingen, DE. We asked, Why is the German experience with commercial CAR T inferior to published study data?
Why is the German experience with commercial CAR T inferior to published study data?
In this video, Bethge discusses the real-world data on the chimeric antigen receptor (CAR) T-cell products, axi-cel and tisa-cel, for patients with relapsed or refractory large B-cell lymphomas from a German registry-based retrospective study. He describes the reasons why progression-free survival and relapse rate were inferior in this trial compared to the pivotal studies, highlighting patient selection as an important factor.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youRelated articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox